OTC Bulletin Board S & P Company Insight for HEMOBIOTECH INC
Profile
	Business Summary: HemoBioTech, Inc. engages in the research and development of human blood substitute technology licensed from Texas Tech University Health Sciences Center (TTUHSC) in Texas. It focuses primarily on the development of HemoTech, an oxygen-carrying solution that performs like red blood cells.   Address   5001 Spring Valley Road   Suite 1040 - West   Dallas , TX 75244   Phone: 972-455-8950   Fax: 972-455-8951   Website: http://www.hemobiotech.com Auditor   Eisner   New York Transfer Agent   Continental Stock Transfer & Trust Co. Employees:  5 ShareHolders:  73 Founded:  2001 Domicile:  Delaware
Background
	HemoBioTech, Inc., in the development stage as of June 30, 2008, engages in the research and development of human blood substitute technology licensed from Texas Tech University Health Sciences Center (TTUHSC) in Texas. It focuses primarily on the development of HemoTech, an oxygen-carrying solution that performs like red blood cells. The company is headquartered in Dallas, Texas. History:  INCORPORATED in Delaware Oct. 30, 2003; and on Dec. 1, 2003, merged a Texas corporation of the same name (Predecessor). Predecessor was incorporated in Texas in December 2001.
Management
	Management Officers Position  Arthur P. Bollon Chairman, President, Chief Executive Officer & Investor Relations Contact  Ghassan  Nino Vice Chairman  Mark J. Rosenblum Secretary & Chief Financial Officer Directors  Robert A. Baron  Arthur P. Bollon  Robert  Comer  Bernhard  Mittemeyer  Ghassan  Nino
Annual Report
	Annual Report   Income Statement   2007 2006 Cost & exps. 3,841 2,658 Interest income 117 141 Interest exp. 1 54 Net income (3,275) (2,571) Share earns. basic ($0.22) ($0.17) Share earns. diluted ($0.22) ($0.17)   Balance Sheet   2007 Assets: Cash & equiv. 2,015 Other curr. assets 521 Tot. curr assets 2,536 Net property 50 Restricted cash 55 Total assets 2,641 Liabilities: Accts. pay. & accruals 254 Tot. curr. liabs. 254 Defr. rent 43 Com. stk. p.$0.001 19 Paid-in cap. 14,186 Retained earns. (11,861) Total liabs. 2,641
Interim Report
	Interim Report      Data Not Available
Pro Forma Report
	Pro Forma Report      Data Not Available
Quarterly Report
	Quarterly Report Information      Quarterly Revenue, US$ Year Quarter Revenue   2008   1 Nil   2008   2 Nil   2007   1 Nil   2007   2 Nil   2007   3 Nil   2007   4 Nil   2007   Full Year Nil   2006   Full Year Nil     Quarterly Net Income, US$ Year Quarter Revenue   2008   1 (740,000)   2008   2 (1,670,000)   2007   1 (830,000)   2007   2 (880,000)   2007   3 (930,000)   2007   4 (1,090,000)     Quarterly EPS, US$ Year Quarter Revenue   2008   1 (.04)   2008   2 (.09)   2007   1 (.05)   2007   2 (.05)   2007   3 (.05)   2007   4 (.06)   2007   Full Year (.22)   2006   Full Year (.17)
Stock Data
	Capitalization as of 06/30/2008:     Authorized Shares Outstanding Shares Common $0.001 par 55,000,000 20,120,791   LONG TERM DEBT: None.   Common $0.001 par   Stockholders:  03/17/2008, 73. PRINCIPAL STOCKHOLDERS: April 24, 2008, Ghassan Nino owned or controlled 17.0% of the Common, Russell Cleveland 15.2%, Bruce Meyers 13.0%, and Arthur P. Bollon 9.6%.   Transfer Agent:  Continental Stock Transfer & Trust Co.   New York , NY   OTC Bulletin Board( Primary): HMBT   Exchange Year High Low OTC Bulletin Board 2007 2.3000 1.2000 OTC Bulletin Board 2006 2.5500 1.2000   RECENT DIVIDENDS: Common $0.001 par: None.